gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · IBOHealthcarePharmaceuticals

Impact BioMedical, Inc. (IBO)

$4.10+1.99%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$4.20▼ 37.50% in range
Nov 3, 2025Low $2.68 · High $84.03Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Impact BioMedical closed at $4.10 on Nov 4, up 1.99%, 95.1% below its 52-week closing high. Volume of 33.7K shares was 1.90× its 20-day average (above normal).

Split-adjusted performance: -12.4% over one month, -48.8% over six months, -39.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $3K, down 57.1% from a year earlier, with a net margin of -23300.0%.

Short interest was 26.3K shares at the Oct 15 settlement, down 12.9% from the prior report (2.6% of float, 2.0 days to cover).

Market cap$35.0M8.5M shares
Revenue · quarter$3.0K−57.1% YoY
Diluted EPS$-0.13—
P/E · TTM44.4×P/S 1,000.8×
Net margin-23,300.0%Gross -533.3%
Dividend yieldNone
52-week range2.68 – 84.03−95.1% from high
Volume33.7K1.90× 20-day avg
Volatility · 60d736.6%Annualised
Short % of float2.6%2.1 days to cover
Net cash$10.0KCash $10.0K
Next earnings—Not scheduled
Split-adjusted performance
1W +2.8%1M −12.4%3M −27.9%6M −48.8%YTD −35.7%1Y −39.0%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum26
Revenue growth19
Net margin3
Value (low P/E)24
Size27

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short26.3K−12.9% vs prior
Days to cover2.1Settled Oct 15
% of float2.6%
Short vol. 10d40.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IBOImpact BioMedical$4.10+1.99%−48.8%−57.1%−23300.0%44.4$35.0M
NNVCNanoViricides$1.38−3.50%−5.5%———$35.2MCompare
BTMDBiote$1.23+9.82%−44.1%−9.5%−14.8%6.0$35.3MCompare
LITSLite Strategy$1.08+3.85%−9.2%———$32.8MCompare
VERUVeru$2.20+1.85%−0.9%———$37.5MCompare
RMTIRockwell Medical, Inc. (DE)$8.05−0.49%−0.6%+10.6%−7.5%—$32.4MCompare
GRCEGrace Therapeutics$1.81−1.63%−23.6%———$38.1MCompare
SCYXSCYNEXIS$3.84−2.54%−51.1%−82.8%3147.7%—$38.2MCompare
PMNProMIS Neurosciences Inc. Common Shares (ON)$3.52+3.23%−68.0%———$31.6MCompare

News about Impact BioMedical

All news →
ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following TreatmentGlobeNewswire Inc. · Oct 23, 2026▲ PositiveCORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)GlobeNewswire Inc. · Sep 15, 2026NeutralImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026GlobeNewswire Inc. · May 30, 2026▲ PositiveImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026GlobeNewswire Inc. · May 16, 2026▲ PositiveImpact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger PlansGlobeNewswire Inc. · Apr 3, 2026▼ Negative

Quick answers

What does Impact BioMedical do?
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
What is IBO's market cap?
$35.03M, based on the Nov 4 close of $4.10.
What is IBO's P/E ratio?
44.4× trailing-twelve-month earnings of $789K.
Does Impact BioMedical pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IBO is sold short?
26.3K shares, 2.6% of float, as of Oct 15, 2026.
What sector is IBO in?
Healthcare, in the Pharmaceuticals industry.

About Impact BioMedical

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.

HQ: Houston, TX8 employeesListed Sep 16, 2024impactbiomedinc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology